November 04, 2015

Research Board Expands Its Membership

Membership to include young veterinarian representative

For the first time in its history, the Respiratory Disease Research Board (formerly the PRRS Research Review Board) will expand its membership in 2016 to include the American Association of Swine Veterinarians’ (AASV) Young Swine Veterinarian of the Year.

The AASV Young Swine Veterinarian of the Year is chosen every March at the association’s annual conference. Dr. Aaron Lower, DVM, of Carthage Veterinary Service, Ltd., in Carthage, Illinois, will be the first to serve in this role, and will be a member of the Respiratory Disease Research Board from January through December 2016.

“Our young veterinarians are the future of swine veterinary medicine,” Dr. Luc Dufresne, Seaboard Foods veterinarian and member of the Respiratory Disease Research Board said. “It’s exciting to have Aaron join our board and to set a foundation for including outstanding young veterinarians in the Research Awards selection process.”

Over the last 12 years, Research Awards totaling $1 million supported development of additional diagnostic testing and sampling processes, identified more effective biosecurity practices, sought to understand virus transmission and developed risk assessment tools, therapeutic intervention programs and vaccination strategies. The program is supported through funding from Boehringer Ingelheim Vetmedica, Inc. (BIVI).

“The challenges swine producers face from PRRS and other respiratory diseases are always changing and evolving,” says Dr. Reid Philips, technical manager, BIVI. “Broadening the perspective and long-term continuity of the Board by including young practitioners will help the industry meet the challenge.”

Practicing veterinarians and researchers seeking an Award for Advancing Research in Respiratory Disease (formerly PRRS Research Awards) need to submit a proposal by January 1, 2016. Additional instructions and submission forms are available at under ‘Download Forms’. Also new in 2016, there will be three (3) $35,000 awards provided and, in addition to PRRS, proposals for research on porcine circovirus type 2 (PCV2), Mycoplasma hyopneumoniae and influenza A virus in swine (IAV-S) will be eligible.

“Swine respiratory diseases are a constant threat to producer profitability,” Dr. Philips says. “That is not likely to change in the foreseeable future, so it is wise to enlist a variety of perspectives in the fight against these diseases. The Research Review Board’s decision to include outstanding young practitioners is a positive step in this direction and one BIVI strongly supports as we plan for the future needs of the swine industry.”

For more information on the Respiratory Disease Research Board and the Research Award program, visit

About the Respiratory Disease Research Board

The Respiratory Disease Research Board, an independent group of swine veterinarians and researchers, selects the Awards for Advancing Research in Respiratory Disease annually. Board members for the 2016 award selection process include:

  • Luc Dufresne, DVM, Seaboard Foods, Shawnee Mission, Kansas
  • Tim Loula, DVM, Swine Vet Center, P.A., St. Peter, Minnesota
  • Daryl Olsen, DVM, AMVC, Audubon, Iowa
  • Montse Torremorell, DVM, Ph.D., University of Minnesota, St. Paul
  • Bill Mengeling, DVM, Ph.D., Diplo. ACVM, Iowa State University, Ames (Retired)
  • AASV President
  • AASV Young Swine Veterinarian of the Year

About Boehringer Ingelheim Vetmedica, Inc.

Boehringer Ingelheim Vetmedica, Inc. (BIVI) is the fifth-largest animal health company in the United States and produces innovative vaccine and pharmaceutical products for the prevention and treatment of diseases in the swine, cattle, equine and companion animal markets. BIVI is the U.S. subsidiary of the global Boehringer Ingelheim Animal Health GmbH. Our U.S. headquarters are located within the KC Animal Health Corridor in St. Joseph, Mo., with other locations in Ames, Fort Dodge and Sioux Center, Iowa.

With more than 3,600 employees worldwide, Boehringer Ingelheim Animal Health achieved net sales of about 1.13 billion euros in 2014. In our research-driven Animal Health business, Boehringer Ingelheim continually invests more than 11 percent of net sales of the Animal Health business in R&D.

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 146 affiliates and a total of more than 47,700 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.

Social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects, such as the initiative “Making more Health” and caring for the employees. Respect, equal opportunities and reconciling career and family form the foundation of the mutual cooperation. In everything it does, the company focuses on environmental protection and sustainability.